证券代码：300639 证券简称：凯普生物 广东凯普生物科技股份有限公司投资者关系活动记录表 编号：2022002 | --- | --- | --- | --- | |------------------------------|------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|------------------------------------------| | | | | | | | 特定对象调研 | □分析师会议 | | | 投 资 者 关 系 活 | □媒体采访 □业绩说明会 | | | | 动类别 | □新闻发布会 □路演活动 | | | | | □现场参观 | | | | | □其他 | （请文字说明其他活动内容） | | | | 方正证券 唐爱金 | 曹佳琳；太平洋证券 ...

广东凯普生物科技股份有限公司 2022 年第三季度报告 证券代码：300639 证券简称：凯普生物 公告编号：2022-121 广东凯普生物科技股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 1,416,056,427.12 | 104.33% | 4,258,583,892.51 | 113.82% | | 归属于上市公司股东的 | 509,856,393.15 | 99.24% | 1,488,168,950.47 | 130.04% | | 净利润（元） | | | | | | 归属于上市公司股东的 扣除非经常性损益的净 | 510,361,207.69 | 106.35% | 1,479,874,914.36 | 135.06% | | 利润（元） | | | | | | 经营活动产 ...

证券代码：300639 证券简称：凯普生物 公告编号：2022-106 广东凯普生物科技股份有限公司 关于参加2022年广东辖区上市公司投资者网上集体接待日 活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的交流沟通，广东凯普生物科技股份有限公司（以下 简称"公司"）将参加由广东证监局和广东上市公司协会共同举办的"2022 年广 东辖区上市公司投资者网上集体接待日"活动，现将有关事项公告如下： 本次投资者网上集体接待日活动将采取网络远程的方式举行，投资者可以登 录"全景• 路演天下"网站（https://rs.p5w.net）参与公司本次投资者网上集 体接待日活动，活动时间为 2022 年 9 月 22 日（星期四）15:50 至 16:50。 届时,公司副总经理兼董事会秘书陈毅先生将通过网络互动形式，与投资者就 公司经营情况及发展战略等方面进行沟通与交流。欢迎广大投资者积极参与。 特此公告。 广东凯普生物科技股份有限公司董事会 二○二二年九月二十一日 ...

Financial Performance - The company reported a revenue of 100 million RMB for the first half of 2022, representing a 20% increase compared to the same period in 2021[16]. - The company's operating revenue reached ¥2,842,527,465.39, representing a year-on-year increase of 118.89%[23]. - The net profit attributable to shareholders was ¥978,312,557.32, up 150.19% compared to the same period last year[23]. - The net profit after deducting non-recurring gains and losses was ¥969,513,706.67, reflecting a growth of 153.64% year-on-year[23]. - The company's total assets at the end of the reporting period were ¥5,799,932,854.73, an increase of 37.07% from the previous year[23]. - The company's self-produced products achieved sales revenue of CNY 531.66 million, a year-on-year increase of 46.17%[37]. - The revenue from purchased products reached CNY 105.63 million, growing by 29.51% year-on-year[37]. - The third-party medical laboratory business generated revenue of CNY 2,205.24 million, reflecting a significant year-on-year growth of 158.42%[39]. - The company achieved operating revenue of 2,842.53 million yuan, a year-on-year increase of 118.89%[49]. - Net profit attributable to shareholders reached 978.31 million yuan, up 150.19% year-on-year[49]. - The company reported a significant increase in revenue, achieving a total of 500 million RMB for the first half of 2022, representing a 25% year-over-year growth[194]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the first half of 2022, representing a year-over-year growth of 25%[196]. Research and Development - The company plans to invest 50 million RMB in R&D for new product development in the next fiscal year[16]. - The company invested ¥86,039,500 in R&D, marking a 55.97% increase year-on-year[32]. - The company emphasizes the importance of R&D in developing new technologies and products to enhance its market position[36]. - The company increased its R&D investment to 86.04 million RMB, representing a year-on-year growth of 55.97%[84]. - Research and development investments increased by 40%, totaling 200 million RMB, aimed at enhancing product offerings and technological advancements[197]. - The company has initiated over 30 new R&D projects focused on maternal and child health, with ongoing clinical trials for HPV-related drugs[60]. Product Development and Launches - The company has successfully launched a new molecular diagnostic product, which is expected to contribute significantly to revenue in the upcoming quarters[16]. - New product launches include a novel nucleic acid extraction kit, which is expected to enhance the company's market position and drive sales growth[90]. - The company has launched two new products in Q2 2022, contributing to a 15% increase in sales volume[200]. - The company is actively developing new technologies and products to enhance its diagnostic capabilities[88]. - The company has developed a range of products including fully automated nucleic acid extraction instruments and various nucleic acid detection kits for HPV and other infectious diseases[36]. - The company has developed a series of molecular diagnostic products in maternal and child health, focusing on cervical cancer HPV screening, maintaining its leadership position in the HPV testing market[55]. Market Expansion - The company has expanded its market presence in Southeast Asia, achieving a 15% market share in the region[16]. - Market expansion efforts are underway, targeting Southeast Asia, with plans to establish partnerships with local distributors by Q4 2022[90]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[196]. - The company is exploring potential acquisitions to enhance its product portfolio, focusing on companies with complementary technologies[89]. Operational Efficiency - The company is enhancing its production capacity and digital transformation to support the upstream and downstream supply chain[61]. - The company has implemented a Manufacturing Execution System (MES) to ensure real-time interaction and quality control during the production process[62]. - A new strategy has been implemented to improve supply chain efficiency, aiming to reduce costs by 15% over the next year[90]. - The company is implementing a new technology platform aimed at improving operational efficiency, projected to reduce costs by 10% annually[194]. Regulatory and Compliance - The company is facing potential risks related to regulatory changes in the healthcare sector, which may impact future operations[3]. - The company has established a strict production and operational management system to comply with regulatory requirements and mitigate risks associated with industry policies and regulations[148]. - The company has received regulatory approval for multiple new diagnostic kits, including the Hepatitis B virus nucleic acid test kit, which is valid until March 1, 2025[88]. Corporate Governance and Social Responsibility - The company has established a comprehensive governance structure, updating various internal regulations to enhance corporate governance and protect shareholder rights[173]. - The company has committed to donating RMB 10 million annually from 2021 to 2023 to support the Guangdong Provincial Basic and Applied Basic Research Fund, totaling RMB 30 million over three years[183]. - The company has actively engaged in social welfare activities, donating over RMB 1.2 million to poverty alleviation projects and supporting educational initiatives[182]. - The company has maintained a commitment to environmental protection, being recognized multiple times as a "Clean Production Enterprise" in Guangdong Province[179]. Shareholder Returns - No cash dividends or stock bonuses will be distributed to shareholders for the current fiscal year[4]. - The company plans to distribute cash dividends amounting to no less than 10% of the distributable profit achieved in the current year[190]. - A cash dividend of 0.5 RMB per share was announced, reflecting the company's commitment to returning value to shareholders[197].

广东凯普生物科技股份有限公司 2022 年第一季度报告全文 证券代码：300639 证券简称：凯普生物 公告编号：2022-047 广东凯普生物科技股份有限公司 2022 年第一季度报告 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 1,510,718,034.62 | 609,471,858.80 | 147.87% | | 归属于上市公司股东的净利润（元） | 499,725,567.45 | 171,939,617.11 | 190.64% | | 归属于上市公司股东的扣除非经常性损 益的净利润（元） | 491,776,771.95 | 163,082,987.01 | 201.55% | | 经营活动产生的现金流量净额（元） | 119,282,306.10 | -49,894,766.64 | 339.07% | | 基本每股收益（元/股） | 1.72 | 0.58 | 196.55% | | 稀释每股收益（元/股） | 1.72 | 0.58 | 196.55% | | 加权平均净资产收益率 | 14 ...

Financial Performance - The company's operating revenue for 2021 was ¥2,673,022,953.56, representing a 97.34% increase compared to ¥1,354,496,759.29 in 2020[19]. - The net profit attributable to shareholders for 2021 was ¥852,160,115.04, a 134.97% increase from ¥362,662,411.14 in 2020[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥840,818,919.67, up 138.15% from ¥353,056,537.12 in 2020[19]. - The company's total assets at the end of 2021 were ¥4,231,385,338.40, an increase of 48.11% from ¥2,856,964,272.70 at the end of 2020[19]. - The basic earnings per share for 2021 was ¥2.91, reflecting an increase of 118.80% compared to ¥1.33 in 2020[19]. - The weighted average return on equity for 2021 was 30.32%, up from 20.70% in 2020, indicating a 9.62% increase[19]. - The company achieved a revenue of 2,673.02 million yuan, representing a year-on-year growth of 97.34%[43]. - The net profit attributable to shareholders reached 852.16 million yuan, with a year-on-year increase of 134.97%[43]. - Total operating revenue for the reporting period reached 2,673.02 million yuan, a year-on-year growth of 97.34%[56]. - Net profit attributable to shareholders was 852.16 million yuan, reflecting a year-on-year increase of 134.97%[56]. Market Expansion and Product Development - The company is focused on expanding its market presence and enhancing its product offerings in the field of in vitro diagnostics[11]. - The company has established 35 third-party medical laboratories across key cities in China, with 30 already operational[42]. - The company is focused on expanding its market presence through the development of new technologies and products in the molecular diagnostics field[49]. - The company has launched multiple new nucleic acid detection kits, including those for COVID-19 and other infectious diseases[48]. - The company is actively engaged in research and development to enhance its diagnostic capabilities and product effectiveness[48]. - The company is focusing on maximizing its market share in the HPV testing and treatment sectors through strategic product development and international registrations[91]. - The company is developing integrated diagnostic solutions for birth defect prevention, including thalassemia gene testing and STD detection products[65]. - The company is expanding its product line to include a new COVID-19 nucleic acid testing kit, expected to be available by April 8, 2026[99]. - The company is actively developing new products, including fully automated nucleic acid extraction systems and various PCR kits, to expand its market presence[102]. Research and Development - The company invested 125.22 million yuan in R&D, marking a 52.39% increase compared to the previous year[42]. - The company has a strong focus on innovation, with 79 patents granted, including 36 invention patents[42]. - The company has established a strong R&D team with 33 PhDs and 176 Master's degree holders, focusing on continuous innovation and product development[73]. - The company aims to enhance its R&D capabilities in molecular diagnostics, focusing on various disease detection products, including HPV and congenital deafness, to strengthen its market position[143]. - The company has initiated research on enzyme raw materials to prepare for domestic alternatives, which will help reduce costs and improve product profitability[92]. - The company is developing a new type of flow cytometry technology for clinical applications, with a focus on prenatal screening and diagnosis[95]. - The company has received approval for 20 new medical testing kits, including tests for Chlamydia, Mycoplasma, and various genetic conditions, with expected market entry dates ranging from 2024 to 2026[98][99]. Operational Efficiency and Cash Flow - The company experienced a significant increase in cash flow from operating activities, with a net cash flow of ¥631,341,752.94, a 102.81% increase from ¥311,300,240.80 in 2020[19]. - Total cash inflow from operating activities increased by 86.53% to CNY 2,227,854,942.90, primarily due to increased cash received from sales of goods and services[106]. - Net cash flow from operating activities rose by 102.81% to CNY 631,341,752.94, reflecting improved operational efficiency[106]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the fiscal year 2021, representing a year-over-year growth of 20%[100]. - The gross margin for the year was reported at 60%, reflecting improved cost management and operational efficiencies[100]. Corporate Governance and Management - The company held 4 shareholder meetings during the reporting period, ensuring compliance with relevant laws and regulations, and guaranteeing equal rights for all shareholders, especially minority shareholders[159]. - A total of 13 board meetings were conducted, with all decisions made in accordance with legal procedures, reflecting the board's commitment to the interests of the company and its shareholders[160]. - The supervisory board convened 11 meetings, effectively overseeing the company's financial status and ensuring compliance by directors and senior management[160]. - The company maintains independence from its controlling shareholders in terms of assets, personnel, finance, organization, and business operations, ensuring no conflicts of interest[161]. - The company has established an independent financial accounting system, enabling it to make autonomous financial decisions without shared bank accounts with controlling shareholders[162]. - The company has a total of 13 directors and supervisors, with the majority not receiving remuneration from related parties[180]. - The company has established a remuneration decision-making process based on the Company Law and its Articles of Association, ensuring transparency and accountability[179]. Industry Trends and Challenges - The molecular diagnostics industry is experiencing rapid growth due to increased demand for nucleic acid testing driven by the COVID-19 pandemic[30]. - The independent medical laboratory market is expected to continue growing due to increasing outsourcing penetration driven by tiered diagnosis and treatment and cost control pressures in hospitals[32]. - The molecular diagnostics sector is expected to continue its rapid growth, driven by increasing healthcare spending and the ongoing demand for nucleic acid testing[136]. - The molecular diagnostics industry is experiencing intensified competition, with an increase in the number of laboratories capable of conducting nucleic acid testing, necessitating continuous innovation and product development to maintain competitive advantage[151]. - As the company expands its business into medical laboratory testing, it faces increased management risks that require timely adjustments to its management systems and practices[153].

广东凯普生物科技股份有限公司 2021 年第三季度报告 证券代码：300639 证券简称：凯普生物 公告编号：2021-110 广东凯普生物科技股份有限公司 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 本报告期比上年同期增 | 年初至报告期末 | 年初至报告期末比上年 | | --- | --- | --- | --- | --- | | | | 减 | | 同期增减 | | 营业收入（元） | 693,008,112.93 | 68.50% | 1,991,641,765.76 | 117.23% | | 归属于上市公司股东的 净利润（元） | 255,901,368.29 | 77.33% | 646,922,270.28 | 136.71% | | 归属于上市公司股东的 扣除非经常性损益的净 | 247,329,518.28 | 76.49% | 629,575,999.62 | 137.51% | | 利润（元） | | | | | | 经营活动产生的现金流 量净额（元） | —— | —— | 258,782,373.78 | 113 ...

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 1,298,633,652.83, representing a 156.88% increase compared to CNY 505,537,512.64 in the same period last year[21]. - The net profit attributable to shareholders of the listed company reached CNY 391,020,901.99, a significant increase of 203.15% from CNY 128,985,345.14 in the previous year[21]. - The net profit after deducting non-recurring gains and losses was CNY 382,246,481.34, up 205.94% from CNY 124,940,856.93 in the same period last year[21]. - The basic earnings per share increased to CNY 1.33, a rise of 171.43% compared to CNY 0.49 in the previous year[21]. - The total assets at the end of the reporting period were CNY 3,544,164,857.98, reflecting a 24.05% increase from CNY 2,856,964,272.70 at the end of the previous year[21]. - The net assets attributable to shareholders of the listed company were CNY 2,654,878,006.91, an increase of 11.06% from CNY 2,390,534,390.08 at the end of the previous year[21]. - The net cash flow from operating activities was CNY 7,417,637.98, which decreased by 82.45% compared to CNY 42,271,345.34 in the same period last year[21]. - The weighted average return on net assets increased by 5.10 percentage points to 15.39% from 10.29% in the previous year[21]. Business Operations and Market Position - The company has developed a series of nucleic acid detection products widely used in clinical diagnosis and public health, establishing a strong market position in cervical cancer screening[28]. - The company has obtained 81 medical device product registrations, including 23 Class III medical device certificates[30]. - The sales revenue from self-produced products was 363.73 million CNY, an increase of 64.28% year-on-year, while revenue from purchased products grew by 95.64% to 81.56 million CNY[30]. - The company has established 32 third-party medical laboratories across the country, with 22 already in operation, enhancing its service network[28]. - The company actively participated in COVID-19 prevention efforts, leading to rapid growth in its nucleic acid testing business during the pandemic[28]. - The company has a strong R&D team with 36 PhDs and 147 master's degree holders, supporting its innovation capabilities[28]. - The company holds 67 patents, including 33 domestic invention patents, enhancing its competitive edge in the market[28]. Research and Development - The company increased its R&D investment to ¥55.16 million, a year-on-year growth of 75.83%, focusing on molecular diagnostics in women's and children's health[48]. - The company has introduced over 30 new R&D projects, primarily in the field of maternal and child health, aiming to enhance clinical registration and rapid deployment of new testing technologies[50]. - The company is focusing on high-end specialty tests such as tumor gene testing and high-density gene chips as part of its growth strategy[35]. - The company is developing innovative products in respiratory virus detection, including COVID-19 and influenza tests, as part of its response to the pandemic[49]. - The company is focused on developing new diagnostic technologies for tumors and infectious diseases[68]. Strategic Initiatives and Future Outlook - The company plans to enhance its online sales platform, aiming for a 20% increase in e-commerce revenue by the end of 2021[73]. - The company is actively pursuing strategic acquisitions, with plans to acquire a smaller biotech firm to enhance its R&D capabilities by Q4 2021[72]. - Market expansion plans include entering two new international markets by the end of 2021, which are projected to increase overall market share by 15%[173]. - The company provided a positive outlook for the second half of 2021, projecting a revenue growth of 30% compared to the first half, aiming for a total revenue of approximately 1.95 billion RMB[174]. Corporate Governance and Compliance - The company emphasizes the quality and timeliness of information disclosure, adhering to principles of transparency and fairness[145]. - The company has maintained strict compliance with commitments made since its listing, with no violations or delays reported[148]. - The company has established detailed regulations regarding related party transactions to ensure fairness and transparency in decision-making processes[165]. - The company emphasizes compliance with regulatory policies and has established a risk prevention mechanism to address potential industry policy and regulatory risks[126]. Community Engagement and Social Responsibility - The company has contributed a total of RMB 317,087.50 in public welfare donations during the reporting period, supporting various charitable activities[153]. - The company established the "Yuechao Women's and Children's Cultural Charity Foundation," donating RMB 321,000 to assist 100 impoverished women in Chaozhou[152]. - The company has been recognized for its contributions to poverty alleviation, receiving honors for its charitable activities in 2020 and 2021[153].

广东凯普生物科技股份有限公司 2021 年第一季度报告全文 广东凯普生物科技股份有限公司 2021 年第一季度报告 （公告编号：2021-041） 2021 年 04 月 1 广东凯普生物科技股份有限公司 2021 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人黄伟雄、主管会计工作负责人李庆辉及会计机构负责人(会计主 管人员)罗翠红声明：保证季度报告中财务报表的真实、准确、完整。 | 项目 | 年初至报告期期末金额 | 说明 | | --- | --- | --- | | 非流动资产处置损益（包括已计提资产减值准备的冲销部分） | 756,120.38 | | | 计入当期损益的政府补助（与企业业务密切相关，按照国家统 | 1,292,313.25 | | | 一标准定额或定量享受的政府补助除外） | | | | 除同公司正常经营业务相关的有效套期保值业务外，持有交易 性金融资产、衍生金融资产、交易性金融负债、 ...

Financial Performance - In 2020, the company's operating revenue reached RMB 1.354 billion, an increase of 85.70% year-on-year[4]. - The net profit attributable to shareholders was RMB 363 million, up 146.22% year-on-year, with a net profit of RMB 353 million after deducting non-recurring gains and losses, representing a growth of 160.87%[4]. - The net cash flow from operating activities was RMB 311 million, reflecting a year-on-year increase of 175.90%[4]. - The company's operating revenue for 2020 was approximately ¥1.35 billion, representing an increase of 85.70% compared to ¥729.39 million in 2019[30]. - The net profit attributable to shareholders for 2020 was approximately ¥362.66 million, a significant increase of 146.22% from ¥147.29 million in 2019[30]. - The basic earnings per share for 2020 was ¥1.66, reflecting a growth of 137.14% compared to ¥0.70 in 2019[31]. - The total assets of the company at the end of 2020 were approximately ¥2.86 billion, an increase of 120.28% from ¥1.30 billion at the end of 2019[31]. - The weighted average return on equity for 2020 was 20.70%, an increase from 14.49% in 2019[31]. - The company achieved total revenue of 1.354 billion yuan, an increase of 85.70% year-on-year[51]. - Net profit reached 394.66 million yuan, up 188.16% compared to the previous year[51]. Product Development and Innovation - The company developed a COVID-19 detection kit within nine days, achieving performance testing results consistent with leading industry standards[5]. - The company invested RMB 409 million in the research and development of nucleic acid molecular diagnostic products, ensuring sufficient funding for future projects[7]. - The company has developed a series of nucleic acid testing products, including HPV detection kits and thalassemia gene testing kits, widely used in clinical testing and population screening[40]. - The company is focused on expanding its product line in genetic disease testing, including tests for Mediterranean anemia and deafness susceptibility genes[41]. - The company has launched new molecular diagnostic instruments, including various models of nucleic acid hybridization instruments and automated extraction devices[42]. - The company has developed three COVID-19 nucleic acid testing products, including PCR-fluorescence probe and Sanger sequencing methods[75]. - The company introduced several new products, including a fully automated nucleic acid extraction and purification instrument (HBNP-9600A) and various nucleic acid extraction kits, enhancing its product portfolio for clinical applications[123]. Market Expansion and Strategic Partnerships - The company plans to expand its third-party medical laboratory network to 50 locations nationwide, with 30 expected to be operational this year[9]. - A strategic partnership was formed with Hunan Youzhe Technology, holding a 20% stake, to develop an intelligent detection system for gynecological microecological analysis[14]. - The company has established a nationwide network of third-party medical laboratories, with 19 already licensed, enhancing its medical testing service capabilities[67]. - The company aims to achieve comprehensive coverage of nucleic acid molecular diagnostic products in the domestic market within 3-5 years, focusing on HPV testing and other key diagnostic products[159]. - The company is exploring potential mergers and acquisitions to accelerate growth and expand its technological capabilities in the biotechnology sector[120]. Research and Development - The company invested 60 million RMB in a key domestic supplier and holds a 2.73% stake in Hangzhou Borui Technology Co., Ltd., a fluorescent PCR instrument manufacturer[14]. - R&D investment reached 82.17 million RMB, a year-on-year increase of 32.83%[75]. - The number of R&D personnel increased to 358 in 2020, representing 21.80% of the total workforce, up from 18.73% in 2019[117]. - The company is committed to continuous innovation in product development and technology to enhance its market position[40]. - The company plans to increase R&D investment and accelerate new product development to enhance its competitive position in the rapidly growing nucleic acid molecular diagnostic market[116]. Operational Capacity and Infrastructure - The production scale of the headquarters in Chaozhou increased fourfold, expanding from 1,800 square meters to 7,100 square meters[13]. - Daily production capacity for hybridization reagents and fluorescent PCR reagents reached 200,000 tests, with nucleic acid extraction and sample preservation solutions also achieving a daily capacity of 200,000 units each[13]. - By 2021, the company plans to increase daily production capacity for extraction reagents to 1 million and for sample preservation solutions to 500,000 based on market demand[13]. - The company has constructed and upgraded laboratory spaces exceeding 26,000 square meters to support its integrated business model of "nucleic acid testing products + medical testing services"[85]. Financial Management and Profit Distribution - The profit distribution plan approved by the board includes a cash dividend of 2.5 RMB per 10 shares and a capital reserve conversion of 2.5 shares per 10 shares[17]. - The total distributable profit at the end of the reporting period was RMB 257.81 million, with the cash dividend representing 100% of the profit distribution[186]. - The company has maintained a consistent cash dividend policy over the past three years, with cash dividends of RMB 58.51 million in 2020, RMB 42.49 million in 2019, and RMB 44.27 million in 2018[187]. - The company has committed to a stable profit distribution policy, ensuring that cash dividends account for at least 10% of the distributable profits each year[194]. Industry Trends and Market Dynamics - The molecular diagnostic sector is experiencing rapid growth, with a compound annual growth rate of 31.63% in China's market from 2013 to 2019[54]. - The COVID-19 pandemic has significantly boosted the demand for nucleic acid testing, presenting a major opportunity for the molecular diagnostics industry[156]. - Increased competition in the molecular diagnostics market is anticipated, prompting the company to focus on new product development, technological innovation, and enhancing its competitive edge[171]. - The independent clinical laboratory (ICL) sector in China grew from 89 ICLs in 2010 to 1,568 by March 2020, with a compound annual growth rate exceeding 30%[58]. Compliance and Governance - The company is committed to maintaining compliance with the Shenzhen Stock Exchange's disclosure requirements for medical device businesses[118]. - The company has established regulations to ensure fair decision-making in related transactions to protect shareholder interests[199]. - The board of directors has committed to strictly follow the company's articles of association regarding related transactions[199].